Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Primary frontal hyperhidrosis is a chronic condition characterized by excessive sweating in the forehead area, which can greatly affect a persons quality of life due to its visibility and impact on daily activities. This research aims to assess the safety and effectiveness of intradermal injections of Botulinum Toxin Type A for treating this condition. Clinical outcomes will be evaluated using the Hyperhidrosis Disease Severity Scale HDSS, Minors iodine-starch test, and patient satisfaction scores, with follow-up one month after treatment to monitor results and side effects. Participants will receive injections of Botulinum Toxin Type A directly into the affected frontal area. The treatment area is identified using Minors iodine-starch test and divided into a grid for precise injection placement. Each injection delivers 2 units of the toxin, with a total dose ranging from 40 to 80 units depending on the size of the affected region. The injections are given using a fine needle, and the treatment is performed during a single visit. During the study, participants will undergo baseline assessments including the HDSS score and Minors test to map sweating areas. One month after treatment, these assessments will be repeated to measure changes in sweating severity and area. Patient satisfaction will also be recorded using a questionnaire. Safety monitoring will include tracking any adverse effects experienced during the follow-up period. The study is conducted on adults aged 18 to 40 years and aims to provide detailed data on treatment effects and safety over this four-week period.
Actively Recruiting
This clinical study is investigating the use of patient-specific 3D-printed titanium implants for reconstructing facial defects and improving facial appearance. It includes adults with congenital, traumatic, or post-surgical facial deformities that require reconstructive surgery. The aim is to evaluate the safety, effectiveness, and functional and aesthetic outcomes of these customized implants compared to traditional methods. Participants will undergo detailed preoperative assessments including clinical exams and high-resolution CT scans. Customized implants are designed using computer-aided design CAD and produced with selective laser melting 3D printing technology from medical-grade titanium. Surgical placement follows standard maxillofacial protocols with fixation to bone as needed. Follow-up includes clinical and radiological exams for up to 12 months after surgery. Throughout the study, participants will have assessments to monitor implant fit, stability, complications, facial symmetry, and patient satisfaction. Outcome measures include postoperative complication rates over six months, implant geometric accuracy immediately after printing, and aesthetic improvement scores at three months. Patient satisfaction and total surgery time are also recorded to evaluate the overall success and safety of this reconstructive approach.
Actively Recruiting
Researchers are investigating the effect of Ursodeoxycholic Acid UDCA combined with triple phototherapy in treating indirect hyperbilirubinemia in newborns born at or after 34 weeks of gestation. This open-label, randomized controlled trial aims to see if adding UDCA can help lower bilirubin levels faster or reduce the time needed for phototherapy compared to phototherapy alone. The study is conducted at Lattakia University Hospital and includes stratification based on jaundice cause, such as hemolytic, non-hemolytic, or G6PD deficiency. Newborns meeting the criteria will be randomly assigned to one of two groups one receiving continuous triple phototherapy alone, and the other receiving the same phototherapy plus oral UDCA at 10 mg per kg per day split into two doses. The UDCA is given with feeding until bilirubin levels fall below the treatment threshold. Phototherapy follows American Academy of Pediatrics guidelines, and participants are monitored closely during treatment. Parents can expect their newborns to have bilirubin levels checked every 12 hours until discharge. The main measures are the time and rate at which bilirubin decreases below phototherapy thresholds within seven days. Secondary outcomes include hospital stay length, bilirubin reduction differences between late preterm and term infants, need for retreatment, and monitoring for any side effects in the UDCA group. The study continues until bilirubin normalizes or treatment ends, with follow-up up to 10 days after discontinuation.